Ko Mi Mi, Jang Soobin, Jung Jeeyoun
Clinical Medicine Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
Medicine (Baltimore). 2019 Feb;98(8):e14543. doi: 10.1097/MD.0000000000014543.
Herbal medicines have the potential to be alternative treatments for metabolic diseases. This systematic review will assess the efficacy of herbal medicines in treating metabolic diseases with blood stasis.
We will search MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, 2 Korean medical databases (OASIS, NDSL), a Chinese database (China National Knowledge Infrastructure, CNKI), and a Japanese database (J-STAGE) for relevant literature. We will include all randomized controlled trials (RCTs) or quasi-RCTs evaluating the effectiveness of herbal medicine. Participants of both sexes and of any age with clinically diagnosed metabolic disease with blood stasis will be included. Primary outcomes will include Blood-stasis syndrome score, TC, TG, HDL-C and LDL-C. Secondary outcomes will Blood pressure, FBS. ECG, prevalence rate of heart disease, and response rate. The risk of bias will be assessed using the Cochrane tool for assessing risk of bias.
The findings of this study will provide a summary of the current state of evidence regarding the effectiveness of types of herbal medicine in managing metabolic disease with blood stasis. In addition, this review will be expected to provide a base for clinical trials to confirm the efficacy of herbal medicine for treatments of metabolic disease with blood stasis.
PROSPERO 2018 CRD42018090179.
草药有可能成为代谢性疾病的替代治疗方法。本系统评价将评估草药治疗血瘀型代谢性疾病的疗效。
我们将检索MEDLINE、Cochrane对照试验中心注册库(CENTRAL)、科学网、两个韩国医学数据库(OASIS、NDSL)、一个中国数据库(中国知网,CNKI)和一个日本数据库(J-STAGE)以获取相关文献。我们将纳入所有评估草药疗效的随机对照试验(RCT)或半随机对照试验。纳入所有临床诊断为血瘀型代谢性疾病的各年龄段男女参与者。主要结局将包括血瘀证评分、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)。次要结局将包括血压、空腹血糖(FBS)、心电图、心脏病患病率及有效率。将使用Cochrane偏倚风险评估工具评估偏倚风险。
本研究结果将总结当前关于各类草药治疗血瘀型代谢性疾病有效性的证据状况。此外,本评价预期将为临床试验提供依据,以证实草药治疗血瘀型代谢性疾病的疗效。
PROSPERO 2018 CRD42018090179。